Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

Launched by ASTRAZENECA · Sep 27, 2022

Keywords

ClinConnect Summary

This clinical trial, called the EPIC study, is looking at how well a medication called acalabrutinib works for patients in the UK who have been diagnosed with chronic lymphocytic leukaemia (CLL). This study is observing patients who started taking acalabrutinib between April 1, 2020, and April 1, 2021, as part of an Early Access Programme. Researchers will gather information from medical records to better understand the characteristics of these patients and how they are doing with this treatment in a real-life setting.

To be eligible for this study, patients must be at least 18 years old and have not received any prior treatment for CLL before starting acalabrutinib. There are no specific exclusions listed, which means that anyone who meets the age and treatment criteria may be included. Participants can expect their medical data to be reviewed, which will help doctors learn more about how acalabrutinib is affecting patients in the UK. This information could be valuable for improving treatments and outcomes for those with CLL in the future.

Gender

ALL

Eligibility criteria

• The study population will include treatment-naïve patients with chronic lymphocytic lymphoma (CLL)\* who meet the following inclusion criteria:
• • Treatment-naïve CLL patients who were initiated on acalabrutinib as part of the UK Early Access Programme
• • Received their first dose of acalabrutinib between 1 April 2020 and 1 April 2021
• • Patients aged ≥18 years old
• • Note: patients later found to have small lymphocytic lymphoma (SLL) may also be included in the EAP.
• Exclusion Criteria:
• • - None listed in study protocol